Management of a 4-Second ECG Pause

Immediate Actions

The American Heart Association recommends initiating continuous ECG monitoring immediately until the bradyarrhythmia resolves or definitive treatment is established 2, 3
Patients with complete heart block or long sinus pauses are prone to develop torsades de pointes, a potentially fatal arrhythmia, as stated by the American College of Cardiology 1, 2
The American Heart Association suggests monitoring for QT-related arrhythmias including enhanced U waves, T wave alternans, polymorphic ventricular premature beats, and nonsustained polymorphic ventricular tachycardia 1, 3

The American College of Cardiology recommends determining if the patient is symptomatic: Look specifically for acute altered mental status, syncope, dizziness, chest discomfort, acute heart failure, hypotension, or other signs of shock 4
Obtain vital signs including blood pressure and oxygen saturation, as suggested by the American Heart Association 4
Perform focused cardiovascular examination for murmurs, gallops, or signs of structural heart disease, as recommended by the American College of Cardiology 5, 6

The American Heart Association recommends performing a 12-lead ECG immediately to better characterize the rhythm and identify underlying substrate for arrhythmias 7, 5, 6
Measure QTc interval carefully, as prolonged QT (>500 ms) combined with pauses creates immediate risk for torsades de pointes, as stated by the American College of Cardiology 1, 2, 3

The American College of Cardiology recommends discontinuing any QT-prolonging or bradycardia-inducing medications immediately, including quinidine, procainamide, disopyramide, sotalol, dofetilide, ibutilide, and certain antipsychotics 1, 2, 3
Review all medications that could contribute to bradycardia (beta-blockers, calcium channel blockers, digoxin), as suggested by the American Heart Association 1
Check potassium and magnesium levels urgently and correct severe abnormalities, as recommended by the American College of Cardiology 1, 2, 3

The American College of Cardiology states that presence of structural heart disease, left ventricular hypertrophy, ischemia, or reduced ejection fraction is a high-risk feature requiring aggressive management 1, 3
QTc prolongation >500 ms is a high-risk feature, as stated by the American Heart Association 1, 2, 3
Female sex, older age, or family history of sudden death are high-risk features, as recommended by the American College of Cardiology 1, 3

The American College of Cardiology recommends that permanent pacemaker implantation should be strongly considered for a 4-second pause, particularly if the patient is symptomatic 2, 3, 7
The American Heart Association suggests continuing monitoring for 12-24 hours after pacemaker implantation 8
If pacemaker is deferred, extended cardiac monitoring (up to 30 days) is recommended to assess for recurrent pauses and paroxysmal arrhythmias, as stated by the American College of Cardiology 9

The American Heart Association recommends considering atropine (0.5-1 mg IV) as first-line therapy for symptomatic bradycardia 4
Transcutaneous pacing pads should be applied for immediate backup pacing capability, as suggested by the American College of Cardiology 4
Avoid medications that could worsen bradycardia, as recommended by the American Heart Association 1, 2

The American College of Cardiology recommends continuing monitoring until the bradyarrhythmia resolves or definitive treatment (permanent pacing) is instituted 2, 3
If QT prolongation is present, continue monitoring until QTc normalizes and no QT-related arrhythmias are observed, as stated by the American Heart Association 1, 2, 3